Literature DB >> 21304506

Pharmacogenetics: Anti-TNF therapy in RA--towards personalized medicine?

Cornelis L Verweij1.   

Abstract

A substantial proportion of patients with rheumatoid arthritis do not respond to tumor necrosis factor blocking therapy. Results of a large genome-wide association study demonstrate evidence of novel genetic factors that determine response to treatment, which could provide a basis for individualizing therapy.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21304506     DOI： 10.1038/nrrheum.2011.13

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  10 in total

Review 1.  Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy.

Authors:  Miguel A Gonzalez-Gay; Carlos Gonzalez-Juanatey; Tomas R Vazquez-Rodriguez; Jose A Miranda-Filloy; Javier Llorca
Journal:  Ann N Y Acad Sci       Date:  2010-04       Impact factor: 5.691

2.  Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Authors:  K L Hyrich; K D Watson; A J Silman; D P M Symmons
Journal:  Rheumatology (Oxford)       Date:  2006-05-16       Impact factor: 7.580

3.  Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis.

Authors:  L G M van Baarsen; C A Wijbrandts; D M Gerlag; F Rustenburg; T C T M van der Pouw Kraan; B A C Dijkmans; P P Tak; C L Verweij
Journal:  Genes Immun       Date:  2010-06-17       Impact factor: 2.676

4.  Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy.

Authors:  Jing Cui; Saedis Saevarsdottir; Brian Thomson; Leonid Padyukov; Annette H M van der Helm-van Mil; Joanne Nititham; Laura B Hughes; Niek de Vries; Soumya Raychaudhuri; Lars Alfredsson; Johan Askling; Sara Wedrén; Bo Ding; Candace Guiducci; Gert Jan Wolbink; J Bart A Crusius; Irene E van der Horst-Bruinsma; Marieke Herenius; Michael E Weinblatt; Nancy A Shadick; Jane Worthington; Franak Batliwalla; Marlena Kern; Ann W Morgan; Anthony G Wilson; John D Isaacs; Kimme Hyrich; Michael F Seldin; Larry W Moreland; Timothy W Behrens; Cornelia F Allaart; Lindsey A Criswell; Tom W J Huizinga; Paul P Tak; S Louis Bridges; Rene E M Toes; Anne Barton; Lars Klareskog; Peter K Gregersen; Elizabeth W Karlson; Robert M Plenge
Journal:  Arthritis Rheum       Date:  2010-07

Review 5.  Rheumatoid arthritis pharmacogenomics.

Authors:  Sara Marsal; Antonio Julià
Journal:  Pharmacogenomics       Date:  2010-05       Impact factor: 2.533

6.  Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis.

Authors:  Marieke J H Coenen; Erik J M Toonen; Hans Scheffer; Timothy R D J Radstake; Pilar Barrera; Barbara Franke
Journal:  Pharmacogenomics       Date:  2007-07       Impact factor: 2.533

7.  Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci.

Authors:  Darren Plant; John Bowes; Catherine Potter; Kimme L Hyrich; Ann W Morgan; Anthony G Wilson; John D Isaacs; Anne Barton
Journal:  Arthritis Rheum       Date:  2011-03

8.  Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment.

Authors:  Lisa Gm van Baarsen; Carla A Wijbrandts; François Rustenburg; Tineke Cantaert; Tineke Ctm van der Pouw Kraan; Dominique L Baeten; Ben Ac Dijkmans; Paul P Tak; Cornelis L Verweij
Journal:  Arthritis Res Ther       Date:  2010-01-22       Impact factor: 5.156

9.  Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis.

Authors:  Wolfgang Hueber; Beren H Tomooka; Franak Batliwalla; Wentian Li; Paul A Monach; Robert J Tibshirani; Ronald F Van Vollenhoven; Jon Lampa; Kazuyoshi Saito; Yoshiya Tanaka; Mark C Genovese; Lars Klareskog; Peter K Gregersen; William H Robinson
Journal:  Arthritis Res Ther       Date:  2009-05-21       Impact factor: 5.156

10.  Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers.

Authors:  Johanna Jakobsdottir; Michael B Gorin; Yvette P Conley; Robert E Ferrell; Daniel E Weeks
Journal:  PLoS Genet       Date:  2009-02-06       Impact factor: 5.917
  10 in total
  5 in total

Review 1.  Pharmacogenetics and pharmacogenomics in rheumatology.

Authors:  Zoltán Szekanecz; Bertalan Meskó; Szilard Poliska; Andrea Váncsa; Szilvia Szamosi; Edit Végh; Enikö Simkovics; Judit Laki; Júlia Kurkó; Timea Besenyei; Katalin Mikecz; Tibor T Glant; László Nagy
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

2.  Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders.

Authors:  Keith J Johnson; Helia N Sanchez; Nancy Schoenbrunner
Journal:  Clin Rheumatol       Date:  2019-09-13       Impact factor: 2.980

3.  Effect of Fcγ-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis.

Authors:  Ildikó Pál; Szilvia Szamosi; Katalin Hodosi; Zoltan Szekanecz; László Váróczy
Journal:  RMD Open       Date:  2017-11-01

4.  Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis.

Authors:  Szilárd Póliska; Timea Besenyei; Edit Végh; Attila Hamar; Anita Pusztai; Andrea Váncsa; Nóra Bodnár; Szilvia Szamosi; Mária Csumita; György Kerekes; Zoltán Szabó; Zoltán Nagy; Gabriella Szűcs; Sándor Szántó; Gábor Zahuczky; László Nagy; Zoltán Szekanecz
Journal:  Arthritis Res Ther       Date:  2019-04-15       Impact factor: 5.156

5.  Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis.

Authors:  Milena Iwaszko; Jerzy Świerkot; Katarzyna Kolossa; Sławomir Jeka; Piotr Wiland; Katarzyna Bogunia-Kubik
Journal:  Genes (Basel)       Date:  2018-01-25       Impact factor: 4.096
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.